$AMN
AMN HEALTHCARE SERVICES INC Stock $amn

$amn Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000114275023000011 Filed on May 05, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$991.3M	$1.126B
YoY Change	-30.51%	-27.46%
Cost Of Revenue	$661.0M	$757.4M
YoY Change	-31.6%	-28.3%
Gross Profit	$330.3M	$368.8M
YoY Change	-28.24%	-25.66%
Gross Profit Margin	33.32%	32.75%
Selling, General & Admin	$201.8M	$205.6M
YoY Change	-17.45%	-20.18%
% of Gross Profit	61.09%	55.74%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$38.23M	$38.83M
YoY Change	15.0%	23.24%
% of Gross Profit	11.58%	10.53%
Operating Expenses	$238.6M	$243.2M
YoY Change	-13.76%	-15.63%
Operating Profit	$91.66M	$125.7M
YoY Change	-50.06%	-39.56%
Interest Expense	$12.18M	$10.26M
YoY Change	20.78%	6.99%
% of Operating Profit	13.28%	8.16%
Other Income/Expense, Net
YoY Change
Pretax Income	$79.49M	$115.4M
YoY Change	-54.17%	-41.81%
Income Tax	$18.58M	$31.30M
% Of Pretax Income	23.38%	27.12%
Net Earnings	$60.91M	$84.11M
YoY Change	-50.8%	-42.39%
Net Earnings / Revenue	6.14%	7.47%
Basic Earnings Per Share	$1.56	$2.03
Diluted Earnings Per Share	$1.55	$2.02
COMMON SHARES
Basic Shares Outstanding	39.65M shares	41.07M shares
Diluted Shares Outstanding	39.34M shares	41.57M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.013M	$28.52M
YoY Change	-91.16%	-74.87%
Cash & Equivalents	$7.013M	$28.52M
Short-Term Investments
Other Short-Term Assets	$34.10M	$51.55M
YoY Change	-37.23%	-8.23%
Inventory
Prepaid Expenses	$17.97M	$26.70M
Receivables	$579.9M	$687.6M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$807.2M	$1.071B
YoY Change	-32.18%	-27.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$177.4M	$155.3M
YoY Change	29.99%	19.76%
Goodwill	$935.8M	$935.3M
YoY Change	0.01%	4.81%
Intangibles	$432.4M	$454.5M
YoY Change	-16.17%	-8.15%
Long-Term Investments
YoY Change
Other Assets	$219.8M	$197.3M
YoY Change	47.93%	18.86%
Total Long-Term Assets	$1.837B	$1.810B
YoY Change	1.01%	2.27%
TOTAL ASSETS
Total Short-Term Assets	$807.2M	$1.071B
Total Long-Term Assets	$1.837B	$1.810B
Total Assets	$2.644B	$2.881B
YoY Change	-12.12%	-11.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$327.5M	$473.8M
YoY Change	-28.64%	-4.73%
Accrued Expenses	$78.33M	$82.34M
YoY Change	-2.35%	-2.39%
Deferred Revenue	$12.39M	$13.88M
YoY Change	-22.28%	-12.31%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$673.7M	$803.6M
YoY Change	-29.63%	-29.97%
LONG-TERM LIABILITIES
Long-Term Debt	$1.034B	$983.8M
YoY Change	22.68%	16.76%
Other Long-Term Liabilities	$163.0M	$121.8M
YoY Change	54.33%	22.8%
Total Long-Term Liabilities	$163.0M	$121.8M
YoY Change	54.33%	22.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$673.7M	$803.6M
Total Long-Term Liabilities	$163.0M	$121.8M
Total Liabilities	$1.878B	$1.925B
YoY Change	-4.65%	-11.18%
SHAREHOLDERS EQUITY
Retained Earnings	$1.386B	$1.325B
YoY Change	29.93%	40.53%
Common Stock	$503.0K	$502.0K
YoY Change	0.6%	0.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$766.3M	$955.8M
YoY Change
Total Liabilities & Shareholders Equity	$2.644B	$2.881B
YoY Change	-12.12%	-11.32%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	$60.91M	$84.11M
YoY Change	-50.8%	-42.39%
Depreciation, Depletion And Amortization	$38.23M	$38.83M
YoY Change	15.0%	23.24%
Cash From Operating Activities	$197.7M	$43.43M
YoY Change	-11.94%	-78.31%
INVESTING ACTIVITIES
Capital Expenditures	$26.45M	$17.49M
YoY Change	-244.68%	28.68%
Acquisitions
YoY Change
Other Investing Activities	$4.021M	-$14.94M
YoY Change	-105.42%	54.88%
Cash From Investing Activities	-$22.43M	-$32.43M
YoY Change	-75.76%	39.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-203.3M	-$44.46M
YoY Change	16.68%	-81.28%
NET CHANGE
Cash From Operating Activities	197.7M	$43.43M
Cash From Investing Activities	-22.43M	-$32.43M
Cash From Financing Activities	-203.3M	-$44.46M
Net Change In Cash	-28.05M	-$33.45M
YoY Change	-33.68%	-44.85%
FREE CASH FLOW
Cash From Operating Activities	$197.7M	$43.43M
Capital Expenditures	$26.45M	$17.49M
Free Cash Flow	$171.2M	$25.95M
YoY Change	-29.47%	-86.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001142750
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-16753
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	AMN HEALTHCARE SERVICES, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1500476
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	8840 Cypress Waters Boulevard
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Dallas
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75019
CY2023Q1	dei	City Area Code CityAreaCode	866
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	871-8519
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	AMN
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39645292	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28516000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64524000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	37736000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	31910000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	687645000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	675650000	usd
CY2023Q1	amn	Accounts Receivable Subcontractor AccountsReceivableSubcontractor	276655000	usd
CY2022Q4	amn	Accounts Receivable Subcontractor AccountsReceivableSubcontractor	268726000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	26696000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18708000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	51552000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	66037000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	1071064000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1093645000	usd
CY2023Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	67594000	usd
CY2022Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	61218000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	233942000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	227617000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	155276000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149276000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	197325000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	172016000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	935319000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	935364000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	379172000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	361327000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	454485000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	476832000	usd
CY2023Q1	us-gaap	Assets Assets	2881063000	usd
CY2022Q4	us-gaap	Assets Assets	2888351000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	473764000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	476452000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	269237000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	333244000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	60600000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	48237000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	803601000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	857933000	usd
CY2023Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	140000000	usd
CY2022Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	0	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	843801000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	843505000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	16113000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	22713000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	121774000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	120566000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1925289000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1844717000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50236000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40238000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50109000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41879000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	502000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	501000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	505857000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	501674000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	9998000	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	8230000	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	874898000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	698598000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1325106000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1240996000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-793000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-939000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	955774000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1043634000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2881063000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2888351000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1126223000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1552538000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	757377000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1056370000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	368846000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	496168000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	205599000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	257579000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	37577000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	30656000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	243176000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	288235000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	125670000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	207933000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	10259000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	9589000	usd
CY2023Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	115411000	usd
CY2022Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	198344000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31301000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52336000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	84110000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	146008000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	146000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-907000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	146000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-907000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	84256000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	145101000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.03
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.11
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.02
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.09
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41378000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46913000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41570000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47208000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1162027000	usd
CY2022Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	228024000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-9431000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11259000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	145101000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1080932000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1043634000	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	176300000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-6134000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10318000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	84256000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	955774000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	84110000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	146008000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38834000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31510000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-505000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-479000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	80000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2023Q1	amn	Accounts Receivable And Sales Credits Credit Loss Expense Reversal AccountsReceivableAndSalesCreditsCreditLossExpenseReversal	25447000	usd
CY2022Q1	amn	Accounts Receivable And Sales Credits Credit Loss Expense Reversal AccountsReceivableAndSalesCreditsCreditLossExpenseReversal	3432000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6639000	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	18526000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10318000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11259000	usd
CY2023Q1	amn	Gain Loss On Disposal Or Impairment Of Long Lived Assets GainLossOnDisposalOrImpairmentOfLongLivedAssets	-1849000	usd
CY2022Q1	amn	Gain Loss On Disposal Or Impairment Of Long Lived Assets GainLossOnDisposalOrImpairmentOfLongLivedAssets	-241000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-81000	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-174000	usd
CY2023Q1	amn	Gain Loss On Deferred Compensation GainLossOnDeferredCompensation	-41000	usd
CY2022Q1	amn	Gain Loss On Deferred Compensation GainLossOnDeferredCompensation	570000	usd
CY2023Q1	amn	Lessee Operating Lease Noncash Expense LesseeOperatingLeaseNoncashExpense	-228000	usd
CY2022Q1	amn	Lessee Operating Lease Noncash Expense LesseeOperatingLeaseNoncashExpense	2880000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	37376000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	194044000	usd
CY2023Q1	amn	Increase Decreasein Accounts Receivablessubcontractor IncreaseDecreaseinAccountsReceivablessubcontractor	7929000	usd
CY2022Q1	amn	Increase Decreasein Accounts Receivablessubcontractor IncreaseDecreaseinAccountsReceivablessubcontractor	50592000	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-8875000	usd
CY2022Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	7988000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-33373000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	115000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-12180000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-221000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	342000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-9557000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	70988000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-71038000	usd
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	96486000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	11903000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	18353000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2040000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-126000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	43434000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	200215000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17487000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13590000	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	usd
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	4018000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2007000	usd
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	6885000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	0	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Trading Securities Heldforinvestment ProceedsFromSaleOfTradingSecuritiesHeldforinvestment	68000	usd
CY2023Q1	us-gaap	Payments To Acquire Life Insurance Policies PaymentsToAcquireLifeInsurancePolicies	16951000	usd
CY2022Q1	us-gaap	Payments To Acquire Life Insurance Policies PaymentsToAcquireLifeInsurancePolicies	12584000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32431000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23239000	usd
CY2023Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	70000000	usd
CY2022Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	210000000	usd
CY2022Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	174744000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	228024000	usd
CY2023Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	3579000	usd
CY2022Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	6134000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	9431000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-44457000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-237455000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-183000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33454000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-60662000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137872000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246714000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104418000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	186052000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	2610000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4230000	usd
CY2023Q1	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	288000	usd
CY2022Q1	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	121000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1053000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	196000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5404000	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9824000	usd
CY2023Q1	amn	Purchaseoffixedassetsrecordedinaccountspayableandaccruedexpenses Purchaseoffixedassetsrecordedinaccountspayableandaccruedexpenses	6849000	usd
CY2022Q1	amn	Purchaseoffixedassetsrecordedinaccountspayableandaccruedexpenses Purchaseoffixedassetsrecordedinaccountspayableandaccruedexpenses	4771000	usd
CY2023Q1	amn	Excise Tax Payable Share Repurchase ExciseTaxPayableShareRepurchase	1556000	usd
CY2022Q1	amn	Excise Tax Payable Share Repurchase ExciseTaxPayableShareRepurchase	0	usd
CY2023Q1	us-gaap	Basis Of Accounting BasisOfAccounting	BASIS OF PRESENTATION<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheets and related condensed consolidated statements of comprehensive income, stockholders’ equity and cash flows contained in this Quarterly Report on Form 10-Q (this “Quarterly Report”), which are unaudited, include the accounts of AMN Healthcare Services, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). All significant intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all entries necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. These entries consisted of all normal recurring items. The results of operations for the interim period are not necessarily indicative of the results to be expected for any other interim period or for the entire fiscal year or for any future period.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements do not include all information and notes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). Please refer to the Company’s audited consolidated financial statements and the related notes for the fiscal year ended December 31, 2022, contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on February 22, 2023 (the “2022 Annual Report”). </span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, including those related to intangible assets purchased in a business combination, asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, contingent consideration liabilities associated with acquisitions, and income taxes. Actual results could differ from those estimates under different assumptions or conditions.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” The new guidance requires companies to apply the definition of a performance obligation under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities, such as deferred revenue, relating to contracts with customers that are acquired in a business combination. Under prior guidance, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at their acquisition-date fair values in accordance with ASC Subtopic 820-10, Fair Value Measurements—Overall. Generally, this new guidance will result in the acquirer recognizing acquired contract assets and liabilities on the same basis that would have been recorded by the acquiree prior to the acquisition under ASC Topic 606. The Company adopted this standard effective January 1, 2023 on a prospective basis, and the adoption did not have a material effect on the Company’s consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents include currency on hand, deposits with financial institutions, money market funds, commercial paper and other highly liquid investments. Restricted cash and cash equivalents primarily includes cash, corporate bonds and commercial paper that serve as collateral for the Company’s captive insurance subsidiary claim payments. See Note (7), “Fair Value Measurement” for additional information.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated balance sheets and related notes to the amounts presented in the accompanying condensed consolidated statements of cash flows.</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,516 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents (included in other current assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, cash equivalents and investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash and investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,610 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,967 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,418 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,872 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and restricted cash in bank deposit accounts primarily at large, national financial institutions, which typically exceed federally insured limits. The Company has not experienced any losses in such accounts.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accounts receivable at the invoiced amount. Accounts receivable are non-interest bearing. The Company maintains an allowance for expected credit losses based on the Company’s historical write-off experience, an assessment of its customers’ financial conditions and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of activity in the allowance for credit losses for accounts receivable:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts written off charged against the allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,736 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,470 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the provision for expected credit losses for the three months ended March 31, 2023 was primarily the result of concern with a specific customer’s ability to meet its financial obligations, and uncertainty regarding the collectability of cash flows from customers due primarily to the current macroeconomic outlook.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To conform to the current year presentation, certain reclassifications have been made to prior year balances in the condensed consolidated balance sheets and accompanying Note (10), “Balance Sheet Details.”</span></div>
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, including those related to intangible assets purchased in a business combination, asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, contingent consideration liabilities associated with acquisitions, and income taxes. Actual results could differ from those estimates under different assumptions or conditions.
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28516000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64524000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	31500000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	37225000	usd
CY2023Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	67594000	usd
CY2022Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	61218000	usd
CY2023Q1	amn	Total Cash Cash Equivalents And Restricted Cash Cash Equivalentsand Investments TotalCashCashEquivalentsAndRestrictedCashCashEquivalentsandInvestments	127610000	usd
CY2022Q4	amn	Total Cash Cash Equivalents And Restricted Cash Cash Equivalentsand Investments TotalCashCashEquivalentsAndRestrictedCashCashEquivalentsandInvestments	162967000	usd
CY2023Q1	us-gaap	Restricted Investments RestrictedInvestments	23192000	usd
CY2022Q4	us-gaap	Restricted Investments RestrictedInvestments	25095000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104418000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137872000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	31910000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	6838000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6938000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1166000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1112000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	534000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	37736000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	7470000	usd
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To conform to the current year presentation, certain reclassifications have been made to prior year balances in the condensed consolidated balance sheets and accompanying Note (10), “Balance Sheet Details.”</span></div>
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	84110000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	146008000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.03
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.11
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.02
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.09
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41378000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46913000	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	192000	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	295000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41570000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47208000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	243000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	160000	shares
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	37577000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	30656000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	1257000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	854000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10318000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11259000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	10259000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	9589000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	115411000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	198344000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	935364000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	935319000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	214939000	usd
CY2023Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	214939000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1126223000	usd
CY2022Q1	amn	Lessee Operating Lease Lease Not Yet Commenced Undiscounted Amount LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount	29514000	usd
CY2022Q1	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1 LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1	P11Y
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1552538000	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	31500000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	37225000	usd
CY2023Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	8875000	usd
CY2023Q1	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	20052000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	19937000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	51552000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	66037000	usd
CY2023Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	54978000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	51408000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	333302000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	323418000	usd
CY2023Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	938000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2067000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	389218000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	376893000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	233942000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	227617000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	155276000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149276000	usd
CY2023Q1	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	140731000	usd
CY2022Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	117139000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14484000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16266000	usd
CY2023Q1	us-gaap	Other Assets Miscellaneous OtherAssetsMiscellaneous	42110000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous OtherAssetsMiscellaneous	38611000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	197325000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	172016000	usd
CY2023Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	81447000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	78057000	usd
CY2023Q1	amn	Accounts Payable To Subcontractor AccountsPayableToSubcontractor	278432000	usd
CY2022Q4	amn	Accounts Payable To Subcontractor AccountsPayableToSubcontractor	295259000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	82337000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	73885000	usd
CY2023Q1	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	15874000	usd
CY2022Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	14638000	usd
CY2023Q1	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	8091000	usd
CY2022Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	7756000	usd
CY2023Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	7583000	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	6857000	usd
CY2023Q1	amn	Accounts Payable And Accrued Expenses Excluding Accrued Compensation And Benefits Current AccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndBenefitsCurrent	473764000	usd
CY2022Q4	amn	Accounts Payable And Accrued Expenses Excluding Accrued Compensation And Benefits Current AccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndBenefitsCurrent	476452000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	72113000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	63857000	usd
CY2023Q1	amn	Accrued Bonuses And Commissions AccruedBonusesAndCommissions	28032000	usd
CY2022Q4	amn	Accrued Bonuses And Commissions AccruedBonusesAndCommissions	96760000	usd
CY2023Q1	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	12394000	usd
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	12113000	usd
CY2023Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	144349000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1786000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	60600000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	48237000	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	128465000	usd
CY2023Q1	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	12349000	usd
CY2022Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	32049000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	269237000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	333244000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	5150000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	5070000	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	23395000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2023Q1	us-gaap	Deposit Liability Current DepositLiabilityCurrent	7463000	usd
CY2022Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	21466000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7789000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8090000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13876000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11825000	usd
CY2023Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	2927000	usd
CY2023Q1	us-gaap	Workers Compensation Liability Noncurrent WorkersCompensationLiabilityNoncurrent	22756000	usd
CY2022Q4	us-gaap	Workers Compensation Liability Noncurrent WorkersCompensationLiabilityNoncurrent	23841000	usd
CY2023Q1	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	38153000	usd
CY2022Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	36214000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7652000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9360000	usd
CY2023Q1	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	53213000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	51151000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	121774000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	120566000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001142750-23-000011-index-headers.html	Edgar Link	pending
0001142750-23-000011-index.html	Edgar Link	pending
0001142750-23-000011.txt	Edgar Link	pending
0001142750-23-000011-xbrl.zip	Edgar Link	pending
amn-20230331.htm	Edgar Link	pending
amn-20230331.xsd	Edgar Link	pending
amn-20230331_g1.jpg	Edgar Link	pending
amn-ex311x20230331x10q.htm	Edgar Link	pending
amn-ex312x20230331x10q.htm	Edgar Link	pending
amn-ex321x20230331x10q.htm	Edgar Link	pending
amn-ex322x20230331x10q.htm	Edgar Link	pending
amn-ex41x2023033110q.htm	Edgar Link	pending
amn-20230331_cal.xml	Edgar Link	unprocessable
amn-20230331_lab.xml	Edgar Link	unprocessable
amn-20230331_pre.xml	Edgar Link	unprocessable
amn-20230331_def.xml	Edgar Link	unprocessable
amn-20230331_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMN
AMN HEALTHCARE SERVICES INC Stock $amn

2023 Q2 Form 10-Q Financial Statement

#000114275023000011 Filed on May 05, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMN AMN HEALTHCARE SERVICES INC Stock $amn

2023 Q2 Form 10-Q Financial Statement

#000114275023000011 Filed on May 05, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMN
AMN HEALTHCARE SERVICES INC Stock $amn